Cargando…
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and with just one recently approved agent (tagraxofusp). It is characterized by the abnormal proliferation of precursor plasmacytoid dendritic cells (pDCs) with morphologic and...
Autores principales: | Beird, Hannah C., Khan, Maliha, Wang, Feng, Alfayez, Mansour, Cai, Tianyu, Zhao, Li, Khoury, Joseph, Futreal, P. Andrew, Konopleva, Marina, Pemmaraju, Naveen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898719/ https://www.ncbi.nlm.nih.gov/pubmed/31811114 http://dx.doi.org/10.1038/s41408-019-0262-0 |
Ejemplares similares
-
Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022) -
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
por: Beird, Hannah, et al.
Publicado: (2023) -
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm
por: Economides, Minas P., et al.
Publicado: (2019) -
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Case
por: Al-Alwan, Ahmad, et al.
Publicado: (2023) -
Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
por: Abla, Dima, et al.
Publicado: (2022)